Form 4: Medtronic EVP Smith's Share Vesting & Tax Withholding

Medtronic's EVP of Global Operations and Supply Chain, Gregory L. Smith, reported the vesting of performance-based equity awards and subsequent share disposals for tax obligations.

Summary

• Gregory L. Smith, Executive Vice President of Global Operations & Supply Chain at Medtronic plc (MDT), reported transactions on August 1, 2025.
• Acquired 11,328 Ordinary Shares at a price of $0 per share, resulting from the settlement of performance-vesting restricted stock units (RSUs) granted on August 1, 2022, which also included earned dividend equivalents.
• Disposed of 4,458 Ordinary Shares at $89.34 per share, which were withheld for taxes upon the settlement of performance-vesting RSUs that vested on August 1, 2025.
• Disposed of an additional 2,656 Ordinary Shares at $89.34 per share, withheld for payment of taxes upon the vesting of restricted stock units previously reported.
• Following these transactions, Smith beneficially owns 75,957 Ordinary Shares directly.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events (vesting and tax-related share disposals). While the vesting of performance shares is positive as it implies performance targets were met, the overall impact is neutral as it's a pre-scheduled event rather than a discretionary purchase or sale indicating new sentiment.

Positives

• The acquisition of 11,328 shares indicates the successful vesting of performance-based equity awards, suggesting that the company met certain performance criteria over the vesting period.
• The vesting of performance share units (PSUs) and restricted stock units (RSUs) demonstrates management's continued alignment with shareholder interests through equity compensation.

Negatives

• The disposal of 7,114 shares (4,458 + 2,656) was solely for tax obligations, which is a common practice but reduces the direct shareholding.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of executive equity compensation vesting and tax-related share disposals, which is a common practice across publicly traded companies, particularly in the medical technology sector like Medtronic, where long-term incentives are a key component of executive compensation structures.

Comparison to Industry Standards

• The type of transaction reported, involving the vesting of performance-based equity and subsequent share withholding for taxes, is standard practice for executive compensation across major corporations.
• This aligns with compensation structures observed in Medtronic's industry peers, such as Johnson & Johnson, Abbott Laboratories, and Stryker Corporation.
• While the specific performance criteria for the share units would be detailed in Medtronic's proxy statements, the mechanism of vesting and tax withholding is consistent with global benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders: The vesting of performance-based equity awards aligns executive incentives with shareholder value creation, as these awards typically vest based on company performance metrics. The subsequent sale of shares for tax purposes is a common, non-discretionary event and does not reflect a change in management's investment outlook.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of performance-based equity awards and the subsequent sale of shares to cover tax obligations. These are pre-scheduled, non-discretionary transactions and do not indicate any new fundamental information about Medtronic's operational performance or future prospects. Therefore, it provides no basis for a change in investment recommendation; a 'hold' stance is maintained based on existing broader company fundamentals and market conditions, not this specific filing.

Keywords

Medtronic, MDT, SEC Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, Performance Share Units, Executive Compensation, Gregory L. Smith, Equity Awards, Tax Withholding